Stage I NSCLC patients who lost IGFBP-3 expression due to the hypermethylation at the CpG sites of IGFBP-3 promoter exhibited statistically lower overall survival (p = 0.022), disease-specific survival probability p = 0.006), and disease-free survival probability p = 0.007) 5 years after diagnosis [67]. The gene discussed is IGFBP3; the disease is non-small cell lung carcinoma.